ATYR2810 / aTyr Pharma - LARVOL DELTA

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) - "The findings demonstrate that ATYR2810 when used as a single agent enhanced anti-tumor immunity and resulted in a significant increase in overall survival. Additionally, when combined with an anti-PD-1 agent, ATYR2810 further increased survival and reduced tumor size. These findings suggest that modulating NRP2 may offer a new approach to reversing the immunosuppressive function of myeloid cells in the tumor microenvironment."

Preclinical • Glioblastoma

Immunosuppressive myeloid cells can be modulated with NRP2-targeting antibody ATYR2810 leading to enhanced anti-tumor immunity (AACR 2025) - "Here we demonstrate that NRP2 is a negative regulator of the inflammatory response and is highly expressed on immunosuppressive myeloid cells in the tumor environment. Blocking NRP2 with ATYR2810 was effective as a single therapy and when combined with checkpoint inhibition in syngeneic tumor models with a high prevalence of MDSCs. This suggests that modulating NRP2 offers a new approach to targeting and reversing the immunosuppressive function of myeloid cells in the tumor microenvironment."

IO biomarker • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • NRP2

Resistance to cancer therapy via upregulation of the NRP2/VEGF-C axis can be neutralized by ATYR2810 (AACR 2023) - "However, sensitivity to chemotherapy was restored when ATYR2810 was used in combination with cisplatin. Here we demonstrate that high levels of VEGF-C expression increase tumor dependency on the VEGF-C/NRP2 signaling axis thereby promoting tumor growth and chemoresistance. ATYR2810 counteracts the aggressive traits of tumors expressing high levels of VEGF-C resulting in enhanced tumor growth inhibition and sensitivity to both chemotherapy and targeted therapy."

Bladder Cancer • Breast Cancer • Clear Cell Renal Cell Carcinoma • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • NRP2 • VEGFC

aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting (GlobeNewswire) - "aTyr Pharma...announced a poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting....Treatment with ATYR2810 monotherapy and in combination with chemotherapy in a model of non-small cell lung cancer demonstrated increased tumor growth inhibition and sensitivity to chemotherapy. In a model of clear cell renal cell carcinoma, ATYR2810 in combination with the VEGFR-targeted therapy sunitinib inhibited tumor growth and led to tumor regression in some cases."

Preclinical • Genito-urinary Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Thoracic Cancer

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update (GlobeNewswire) - "...'As part of this prioritization, we have made the strategic decision not to use internal resources to initiate a Phase 1 study of ATYR2810 this year. The data we have generated for ATYR2810 firmly support its therapeutic potential in rare aggressive tumors, thus we intend to pursue alternative non-dilutive funding avenues, including academic collaborations, to advance this program'."

Commercial • Licensing / partnership • Oncology

aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting (GlobeNewswire) - "aTyr Pharma...announced a poster presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting....ATYR2810 monotherapy inhibited spontaneous lung metastasis in an experimental model of TNBC, demonstrating the potential therapeutic effects of blocking the NRP2/VEGF signaling axis on preventing tumor persistence....'We look forward to advancing ATYR2810 to a Phase 1 study in cancer patients in the second half of the year'."

New P1 trial • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

ATYR2810, a fully humanized monoclonal antibody targeting the VEGF-NRP2 pathway sensitizes highly aggressive and chemoresistant TNBC subtypes to chemotherapy (AACR 2022) - "Interestingly, the chemokine receptor CXCR4, which is known to promote drug resistance and tumorigenic potential, was found to be significantly downregulated in responder PDX tumors treated with ATYR2810 in combination with cisplatin as compared to those treated with cisplatin alone. Taken together, our data suggest that ATYR2810 enhances chemosensitivity in highly aggressive TNBC subtypes, and that this response may be mediated through the downregulation of genes known to be associated with aggressive cancer states such as ZEB1 and CXCR4. ATYR2810 may therefore serve as a novel therapeutic agent for the treatment of advanced and metastatic TNBC and potentially other aggressive cancer types.Zhiwen Xu and Alison Barber are co-first authors of this abstract."

Late-breaking abstract • HER2 Breast Cancer • Oncology • Triple Negative Breast Cancer • CXCR4 • HER-2 • NRP2 • ZEB1

aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting (Yahoo Finance) - "aTyr Pharma, Inc...announced that the company will present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8 – 13, 2022, in New Orleans, LA, and virtually."

Preclinical • Breast Cancer • Oncology • Triple Negative Breast Cancer

ATYR2810 an anti-NRP2 monoclonal antibody targets tumor-associated macrophages (SITC 2021) - "We show for the first time that NRP2 has the ability to regulate ZEB1 expression in TAMs; reducing their suppressive nature, pointing to a novel role of NRP2 in TAMs. These findings indicate ATYR2810s potential to be an effective anti-cancer agent through regulation of ZEB1 in both TAMs and tumors."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • NRP2 • ZEB1

aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update (GlobeNewswire) - "These data advance the understanding of ATYR2810’s mechanism of action and the process by which it may inhibit tumor progression and disrupt immune invasion and will support clinical development for ATYR2810, including a planned Phase 1 study in cancer next year."

New P1 trial • Breast Cancer • Oncology

aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) - "The poster presents preclinical findings for ATYR2810, providing key insights into its mechanism of action that will help support the clinical development of ATYR2810, including a Phase 1 study in cancer next year....This work details the effects of ATYR2810 on tumor associated macrophages (TAMs) differentiated from human triple-negative breast cancer tumor cells. Treatment with ATYR2810 was shown to decrease the suppressive capabilities of TAMs against T cells compared to untreated TAMs."

New P1 trial • Preclinical • Breast Cancer • Oncology

aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) - "aTyr Pharma, Inc...announced that the company will present a poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being held November 10 – 14, 2021 in Washington, DC, and virtually."

Clinical data • Oncology

[VIRTUAL] A domain-specific antibody to NRP2 down-regulated epithelial-mesenchymal transition genes and enhanced efficacy of standard-of-care therapeutics for aggressive breast cancer (AACR 2021) - "We have shown that ATYR2810, but not a Sema3F-blocking mAb has tumor-inhibitory effects on triple negative breast cancer (TNBC) cell lines or patient-derived organoids. We further evaluated the efficacy of ATYR2810 in combination with standard-of-care therapeutics including Cisplatin and Bevacizumab (anti-VEGF-A blocking antibody). These results demonstrate the efficacy of ATYR2810 in combination with standard-of-care therapeutics in in vitro and in vivo TNBC models, and suggest its activity is mediated through inhibiting both EMT and cellular dedifferentiation that renders tumors more sensitive to the treatment regimes. The targeting of VEGF/NRP2 signaling by ATYR2810 may provide a new therapeutic option, and lead to the identification of new treatment biomarkers, which could offer improved efficacy and reduced toxicity in aggressive breast cancers."

Clinical • Late-breaking abstract • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • NRP2 • ZEB1

[VIRTUAL] The Neuropilin-2 targeting antibody ATYR2810 inhibits non-small cell lung cancer tumor growth in monotherapy and combination therapy (AACR 2021) - "The effects of ATYR2810 combination therapy in NSCLC xenografts was also examined, and we found that the use of ATYR2810 in combination with either 5-FU or cisplatin enhanced tumor growth inhibition as compared to the use of either chemotherapeutic agent alone. Taken together, these results suggest that NRP2 may be an important target in aggressive NSCLC and that the use of our novel ATYR2810 antibody to block VEGF-mediated NRP2 signaling may serve as a valuable therapeutic agent both as monotherapy as well as in combination therapy."

Combination therapy • Late-breaking abstract • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • NRP2

aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810 (GlobeNewswire) - “aTyr Pharma, Inc…announced that it will present a poster and participate in a live Q&A session at the Virtual Keystone Symposia on Cancer Stem Cells: Advances in Biology and Clinical Translation, which is being held May 19 – 21, 2021….The poster presents preclinical findings demonstrating that ATYR2810, a Neuropilin-2 (NRP2) antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes patient-derived xenograft models of triple-negative breast cancer (TNBC) to chemotherapy. Furthermore, gene expression data from TNBC xenograft samples and patient derived organoids show that ATYR2810 downregulates several cancer stem cell and epithelial-mesenchymal transition (EMT) markers.”

Preclinical • Breast Cancer • Oncology • Triple Negative Breast Cancer

aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810 (GlobeNewswire) - “aTyr Pharma, Inc…announced that the companies have entered into an agreement for the manufacture of ATYR2810, aTyr’s monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer. Under the terms of the agreement, Lonza will utilize its Ibex® Design, a fully integrated end-to-end program, to manufacture cGMP material for ATYR2810. The agreement will cover the early stages from gene to Investigational New Drug (IND) and will provide both drug substance (DS) and drug product (DP) to support toxicological studies in animals and early clinical development in humans.”

Licensing / partnership • Oncology

aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting (GlobeNewswire) - “aTyr Pharma…announced two poster presentations at the 2021 American Association for Cancer Research (AACR) Annual Meeting, which is being held virtually April 10 – 15 and May 17 – 21, 2021…In animal models of non-small cell lung cancer, ATYR2810 administered therapeutically as a single agent significantly inhibited tumor growth. When administered in combination with chemotherapy, including either 5-FU or cisplatin...In models of triple-negative breast cancer (TNBC), ATYR2810 administered in combination with widely used anti-cancer therapeutics, including the chemotherapeutic agent cisplatin or the targeted VEGF therapy bevacizumab, increased the anti-tumor effects of each agent."

Preclinical • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Triple Negative Breast Cancer

aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "aTyr Pharma, Inc...announced that the company will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held virtually April 10 – 15 and May 17 – 21...Title: The Neuropilin-2 targeting antibody ATYR2810 inhibits non-small cell lung cancer tumor growth in monotherapy and combination therapy; Title: A domain-specific antibody to NRP2 down-regulated epithelial-mesenchymal transition genes and enhanced efficacy of standard-of-care therapeutics for aggressive breast cancer"

Preclinical • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology

aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression (GlobeNewswire) - "aTyr Pharma...today announced that it will present a poster and participate in a live Q&A session at the Virtual Keystone Symposia: Tumor Metabolism and the Microenvironment, which is being held January 25 – 28, 2021...The poster presents preclinical findings demonstrating that Neuropilin-2 (NRP2) was highly expressed on key immune cells implicated in regulating cancer progression...Our panel of highly specific antibodies selectively targeting NRP2, such as our lead IND candidate ATYR2810, may present differentiated approaches to treating certain aggressive cancers where NRP2 is implicated."

Preclinical • Oncology • Solid Tumor